-
Sumatriptan Metabolism Revisited: CYP and MAO Evidence
2026-08-20
The reference study challenges the established view that sumatriptan is metabolized mainly through monoamine oxidase A (MAO A). Using recombinant human enzymes and HPLC–MS, it demonstrates sequential cytochrome P450 demethylation followed by MAO A oxidation, clarifying how enzyme identity and metabolite structure shape the drug’s metabolic fate.
-
Lypressin acetate: Assays, Workflows, and Use-Cases
2026-08-20
Lypressin acetate connects vasopressin-receptor pharmacology with practical antidiuretic, vascular, and exploratory antiviral workflows. This guide emphasizes assay selection, quantitative controls, peptide handling, and troubleshooting so researchers can distinguish receptor activity from formulation or matrix artifacts.
-
Doxycycline: From MMP Inhibitor to Targeted AAA Therapy
2026-08-19
Doxycycline is more than a tetracycline antibiotic: its metalloproteinase inhibition is being re-engineered for targeted abdominal aortic aneurysm research. This article explains how nanoparticle delivery changes assay design, interpretation, and translational strategy.
-
Filipin III for Membrane Cholesterol Visualization
2026-08-19
Filipin III combines sterol-sensitive fluorescence with ultrastructural readouts, making it useful for cell imaging, membrane-fraction assays, vesicle validation, and freeze-fracture electron microscopy. This practical guide connects cholesterol mapping to the CAV1–cholesterol-homeostasis mechanism reported in MASLD research while emphasizing controls, handling, and interpretation limits.
-
SB-3CT Workflows for MMP-2/MMP-9 Research
2026-08-18
SB-3CT enables focused control of MMP-2 and MMP-9 in biochemical, tumor metastasis, and perineuronal-net assays. This guide turns its gelatinase selectivity into practical workflows, dose-planning logic, and troubleshooting strategies for cancer and neurobiology researchers.
-
CUDC-907: Practical PI3K/HDAC Workflow
2026-08-18
CUDC-907 provides a research tool for examining coordinated PI3K and HDAC inhibition in cancer cell models, including pathway signaling, epigenetic response, cell-cycle distribution, and apoptosis. It is intended for controlled scientific workflows only and should not be used for diagnostic, therapeutic, or clinical applications.
-
GM 6001: Translating MMP Biology into Strategy
2026-08-17
GM 6001 (Galardin) is more than a broad-spectrum MMP inhibitor: it is a mechanistic tool for separating extracellular matrix remodeling, protease-driven signaling, and context-dependent cell phenotypes. This thought-leadership guide shows how translational researchers can use it to connect tissue repair, EGFR signaling, vascular remodeling, and cancer biology without overstating what the evidence proves.
-
GM 6001 (Galardin) for ECM Research
2026-08-17
GM 6001 (Galardin) provides broad MMP suppression for experiments spanning perineuronal-net preservation, tissue remodeling, signaling, and cell migration. This workflow-focused guide shows how to pair its nanomolar biochemical profile with spatial, functional, and activity-based readouts while avoiding common interpretation and handling errors.
-
SAR131675: VEGFR-3 Assay Design for Fibrosis
2026-08-16
SAR131675 is a selective VEGFR-3 inhibitor for dissecting VEGFC-dependent lymphatic, endothelial, and macrophage biology. This guide translates a recent hepatic fibrosis study into a practical, mechanism-centered assay strategy rather than another general tumor-model overview.
-
SGI-1027 and Everolimus Trigger Lysosomal Death
2026-08-15
This 2024 Advanced Science study identifies SGI-1027 as a methuosis-inducing cytotoxic agent and shows that it cooperates with everolimus to suppress renal cancer growth, migration, and invasion. The combination links lysosomal membrane permeabilization with apoptosis and GSDME-dependent pyroptosis, providing a preclinical strategy for addressing everolimus resistance in renal cell carcinoma.
-
AL-8810: From FP Signaling to Translational Insight
2026-08-14
AL-8810 is a selective prostaglandin F2α antagonist that enables receptor-level interrogation of PGF2α/PTGFR biology. This thought-leadership article connects its pharmacology with endometrial breakdown, vascular remodeling, smooth muscle signaling, and translational study design while distinguishing evidence-supported findings from forward-looking research strategy.
-
From CSRP2 Biology to Better Glioma Protein Data
2026-08-14
The CSRP2–PRC1–PDGFRA/PI3K/AKT model illustrates why translational glioma studies need protein workflows that preserve both abundance and signaling state. This thought-leadership guide explains where RIPA Lysis Buffer (Strong) adds value, where its detergent strength requires caution, and how to connect extraction quality with mechanistic confidence.
-
SB-3CT Workflows for MMP-9 and ECM Research
2026-08-13
SB-3CT is a selective gelatinase inhibitor for separating MMP-2/MMP-9 activity from broader extracellular-matrix effects. This guide translates recent perineuronal-net findings into practical CNS assays while also outlining applications in tumor metastasis research, angiogenesis inhibition, and ischemia models.
-
Sulfachloropyridazine: Applied Research Workflows
2026-08-13
Build more reproducible folate-pathway experiments with Sulfachloropyridazine, from DHPS enzyme inhibition assays and antimicrobial susceptibility testing to integrated microbiome–metabolome studies. The workflow connects direct antibacterial activity with community-level effects while highlighting solvent, control, and interpretation safeguards.
-
Xenopus Hybridization Rewired the Pluripotency Network
2026-08-12
Phelps and colleagues show that hybridization reshaped early developmental gene regulation in allotetraploid Xenopus laevis without disrupting overall pluripotency-associated dosage. Homeolog-resolved RNA sequencing, chromatin profiling, and transcription-factor mapping reveal divergent L- and S-subgenome activation that is balanced at the level of combined gene output.